Abstract 237P
Background
There is paucity of data of role of PARP inhibitors (PARPi) in BRCA mutation (gBRCAm) positive platinum resistant ovarian cancer (OC) disease. We report here analysis of outcome of PARPi treatment in patients including those with platinum resistant disease.
Methods
In this study, we analyzed efficacy of PARPi in all consecutive patients of OC with gBRCAm who received the drug. The drug was procured through compassionate program.
Results
Between July 1, 2015 and June 30, 2019, 28 patients received PARPi. At the time of data censoring (June 30, 2019), 6 (21.4%) patients are still on treatment. 5 patient received Talazoparib and 23 Olaparib. Median age is 54.5 years (range 39-75). BRCAm 1 positive patients were 20. Median number of previous lines of chemotherapy received were 3 (range 1-6). 7 platinum sensitive patients received the drug as maintenance (3 in complete response [CR] and 4 in partial response [PR]) while 21 had platinum resistant progressive disease. Overall response rate (ORR) was 82% with CR as the best response in 5 which also includes 3 patients who received the drug while in CR and maintained it. With the median treatment duration (mTD) of 14.14 months (95%CI 8.43-23.33), 71.4 % patients eventually progressed. The median follow up was 15.3 months (range 4- 42.6 months). The median overall survival (OS) was 32.9 months (95% CI 13.03 NR) The below table describes results of 21 platinum resistant patients. With the mTD of 10.4 months (95%CI 8.17 23.33), 86 % patients had progressed. Three (14%) platinum resistant patients are still on treatment with the treatment duration (TD) of 5.47, 32.9 and 37 months.
Table: 237P
Response | N (%) |
---|---|
ORR | 16 (76) |
CR | 1 (4.7) |
PR | 15 (71.4) |
PD | 5 (24) |
Median OS in months (95% CI) | 28.8 (9.6 NR) |
Progression free survival was not calculated as disease assessment was not done at defined time point. The TD was taken as the surrogate marker for efficacy. Grade ≥3 side effects were documented in 33% patients (anemia 23.5%, thrombocytopenia 17.6%, fatigue 25%).
Conclusions
This study suggests that PARPi is a viable treatment option in patients of platinum resistant OC with gBRCAm. This should be further evaluated in randomized clinical controlled trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amit Agarwal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract